Trial Profile

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in children and adolescents aged 0-18 years with CD19+ acute lymphoblastic leukaemia resistant or refractory to treatment. - CART19-BE-03Ped

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varnimcabtagene-Autoleucel (Primary) ; Allopurinol; Cyclophosphamide; Cytarabine; Dexchlorpheniramine; Dexchlorpheniramine; Etoposide; Fludarabine; Immunoglobulin G; Methylprednisolone; Paracetamol; Tocilizumab
Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms CART19-BE-03Ped

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com